BCLI
Price
$1.16
Change
-$0.01 (-0.85%)
Updated
Jul 3 closing price
Capitalization
11.41M
EYPT
Price
$9.66
Change
-$0.00 (-0.00%)
Updated
Jul 3 closing price
Capitalization
668.85M
24 days until earnings call
Interact to see
Advertisement

BCLI vs EYPT

Header iconBCLI vs EYPT Comparison
Open Charts BCLI vs EYPTBanner chart's image
Brainstorm Cell Therapeutics
Price$1.16
Change-$0.01 (-0.85%)
Volume$98.01K
Capitalization11.41M
EyePoint Pharmaceuticals
Price$9.66
Change-$0.00 (-0.00%)
Volume$1.03K
Capitalization668.85M
BCLI vs EYPT Comparison Chart in %
Loading...
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCLI vs. EYPT commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCLI is a Hold and EYPT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (BCLI: $1.16 vs. EYPT: $9.72)
Brand notoriety: BCLI and EYPT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCLI: 6% vs. EYPT: 44%
Market capitalization -- BCLI: $11.41M vs. EYPT: $668.85M
BCLI [@Biotechnology] is valued at $11.41M. EYPT’s [@Biotechnology] market capitalization is $668.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCLI’s FA Score shows that 0 FA rating(s) are green whileEYPT’s FA Score has 1 green FA rating(s).

  • BCLI’s FA Score: 0 green, 5 red.
  • EYPT’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than BCLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCLI’s TA Score shows that 4 TA indicator(s) are bullish while EYPT’s TA Score has 4 bullish TA indicator(s).

  • BCLI’s TA Score: 4 bullish, 5 bearish.
  • EYPT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both BCLI and EYPT are a bad buy in the short-term.

Price Growth

BCLI (@Biotechnology) experienced а +6.42% price change this week, while EYPT (@Biotechnology) price change was -6.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

BCLI is expected to report earnings on May 15, 2025.

EYPT is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($669M) has a higher market cap than BCLI($11.4M). EYPT YTD gains are higher at: 30.470 vs. BCLI (-48.899). BCLI has higher annual earnings (EBITDA): -12.08M vs. EYPT (-144.55M). EYPT has more cash in the bank: 318M vs. BCLI (1.64M). BCLI has less debt than EYPT: BCLI (1.77M) vs EYPT (24.1M). EYPT has higher revenues than BCLI: EYPT (56M) vs BCLI (0).
BCLIEYPTBCLI / EYPT
Capitalization11.4M669M2%
EBITDA-12.08M-144.55M8%
Gain YTD-48.89930.470-160%
P/E RatioN/AN/A-
Revenue056M-
Total Cash1.64M318M1%
Total Debt1.77M24.1M7%
FUNDAMENTALS RATINGS
BCLI vs EYPT: Fundamental Ratings
BCLI
EYPT
OUTLOOK RATING
1..100
5075
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6437
P/E GROWTH RATING
1..100
10017
SEASONALITY SCORE
1..100
850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EYPT's Valuation (61) in the Pharmaceuticals Major industry is in the same range as BCLI (89) in the Computer Peripherals industry. This means that EYPT’s stock grew similarly to BCLI’s over the last 12 months.

EYPT's Profit vs Risk Rating (98) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that EYPT’s stock grew similarly to BCLI’s over the last 12 months.

EYPT's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that EYPT’s stock grew similarly to BCLI’s over the last 12 months.

EYPT's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as BCLI (64) in the Computer Peripherals industry. This means that EYPT’s stock grew similarly to BCLI’s over the last 12 months.

EYPT's P/E Growth Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for BCLI (100) in the Computer Peripherals industry. This means that EYPT’s stock grew significantly faster than BCLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCLIEYPT
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
78%
Momentum
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 17 days ago
82%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
89%
Aroon
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 4 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
BCLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EP5.630.24
+4.45%
Empire Petroleum Corp
BCDA2.120.04
+1.73%
BioCardia Inc.
SDA2.540.04
+1.60%
SunCar Technology Group
BNL16.340.03
+0.18%
Broadstone Net Lease
K80.00N/A
N/A
Kellanova

BCLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCLI has been loosely correlated with VBIZF. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BCLI jumps, then VBIZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCLI
1D Price
Change %
BCLI100%
-0.85%
VBIZF - BCLI
35%
Loosely correlated
N/A
ATHE - BCLI
35%
Loosely correlated
+2.64%
BLRX - BCLI
30%
Poorly correlated
-2.60%
XTLB - BCLI
29%
Poorly correlated
+10.00%
EYPT - BCLI
28%
Poorly correlated
+0.62%
More

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
+0.62%
LYRA - EYPT
58%
Loosely correlated
-3.33%
OCUL - EYPT
58%
Loosely correlated
+1.69%
ATHE - EYPT
54%
Loosely correlated
+2.64%
CRSP - EYPT
53%
Loosely correlated
+0.97%
BEAM - EYPT
53%
Loosely correlated
+0.65%
More